⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.

ALHC — Alignment Healthcare, Inc.

Last scan (Sept. 18, 2026): price $8.70, RSI 17.50, relative volume 3.89x, MACD ⚪ No, score 50.00.

It's trading below its 200-day average, with an RSI of 17.5 in oversold territory — technically weak, though that can also signal the pessimism is already priced in. Neither the MACD nor a range breakout gives a technical entry signal right now. Today's volume is 3.89x average — well above normal activity, a sign of real interest. The analysts' average target price implies +155.5% upside — one of the score's strongest signals. Today it holds rank #2 in the Standard group on Smart Scanner's upside + relative volume ranking.

back to scanner

Price chart

Price: $nan · RSI (14): 17.5 · Rel. volume: 2.75x · Breakout: No

You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.

What analysts say

ALHC

Alignment Healthcare, Inc. Healthcare · Healthcare Plans

Alignment Healthcare, Inc. operates a consumer-centric healthcare platform for seniors in the United States. It delivers customized healthcare experience to meet the needs of seniors through its Medicare Advantage plans. Alignment Healthcare, Inc. was founded in 2013 and is based in Orange, California.

Strong buy score 1.5/5 (1 = strong buy, 5 = sell)
14 analysts
  • Buy 12 (85.7%)
  • Hold 2 (14.3%)
  • Sell 0 (0.0%)

Average target price: $22.23 (+166.2% vs. current price) · range $13.0 – $28.0

Healthy Moderate Attention No data

Market cap $1.73B

Total market value of the company (price × shares outstanding).

P/E (trailing) 43.95

P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.

High: the market is paying a premium, usually because it expects strong growth. If the company doesn't deliver, the price could correct sharply.

P/E (forward) 11.1

P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.

Same as P/E, using estimated future earnings.

PEG N/A

PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.

Not enough data (requires future growth estimates).

Debt/Equity 124.66%

Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.

Moderate leverage, normal in many industries.

Net margin 0.89%

Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.

Low margin: the business has little cushion if costs rise.

Dividend N/A

Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.

Doesn't pay dividends: reinvests earnings into growth instead of distributing them.

Beta (risk) 1.11

Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).

Moves similarly to the overall market.

General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.

💰 Financial Statements (last 3 quarters)

💰 Financial Statements (last 3 quarters)

Advertisement

What this chart shows

Third-party market data, for informational purposes. Not investment advice — read the disclaimer.